Does the media prefer BIIB or IONS?

In the previous week, Biogen had 6 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 16 mentions for Biogen and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Biogen's score of 1.52 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 13 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ionis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ALNY or IONS?

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Alnylam Pharmaceuticals' score of 0.22 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to IONS or INSM?

In the previous week, Ionis Pharmaceuticals and Ionis Pharmaceuticals both had 10 articles in the media. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Insmed's score of 0.82 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or IONS?

In the previous week, Roivant Sciences had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 13 mentions for Roivant Sciences and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Roivant Sciences' score of 0.52 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor MRNA or IONS?

In the previous week, Moderna had 40 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 50 mentions for Moderna and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Moderna's score of 0.67 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 28 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 6 Very Negative mention(s) Positive Ionis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Ionis Pharmaceuticals (IONS) Competitors

$60.80 +1.18 (+1.98%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$60.63 -0.17 (-0.29%)

As of 04:29 AM Eastern

Compare

IONS vs. BIIB, ALNY, INSM, ROIV, and MRNA

Should you buy Ionis Pharmaceuticals stock or one of its competitors? Ionis Pharmaceuticals's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ionis Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.26	$1.29B	$5.65	39.21
Ionis Pharmaceuticals	$944M	10.70	-$381.39M	-$3.46	N/A

87.9% of Biogen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to Ionis Pharmaceuticals' net margin of -64.76%. Biogen's return on equity of 11.18% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

In the previous week, Biogen had 6 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 16 mentions for Biogen and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Biogen's score of 1.52 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	13 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ionis Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biogen presently has a consensus price target of $227.07, indicating a potential upside of 2.49%. Ionis Pharmaceuticals has a consensus price target of $94.15, indicating a potential upside of 54.85%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Biogen beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Alnylam Pharmaceuticals' score of 0.22 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Ionis Pharmaceuticals' net margin of -64.76%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Alnylam Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.76	$313.75M	$5.38	45.09
Ionis Pharmaceuticals	$944M	10.70	-$381.39M	-$3.46	N/A

Alnylam Pharmaceuticals presently has a consensus target price of $386.62, suggesting a potential upside of 59.36%. Ionis Pharmaceuticals has a consensus target price of $94.15, suggesting a potential upside of 54.85%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Alnylam Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Insmed?

Ionis Pharmaceuticals (NASDAQ:IONS) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Ionis Pharmaceuticals and Ionis Pharmaceuticals both had 10 articles in the media. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Insmed's score of 0.82 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	10.70	-$381.39M	-$3.46	N/A
Insmed	$606.42M	47.05	-$1.28B	-$4.11	N/A

Ionis Pharmaceuticals has a net margin of -64.76% compared to Insmed's net margin of -76.94%. Ionis Pharmaceuticals' return on equity of -111.08% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Insmed	-76.94%	-123.94%	-44.30%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ionis Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus target price of $94.15, indicating a potential upside of 54.85%. Insmed has a consensus target price of $205.52, indicating a potential upside of 57.30%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Ionis Pharmaceuticals beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Roivant Sciences presently has a consensus target price of $35.14, indicating a potential downside of 6.05%. Ionis Pharmaceuticals has a consensus target price of $94.15, indicating a potential upside of 54.85%. Given Ionis Pharmaceuticals' higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

In the previous week, Roivant Sciences had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 13 mentions for Roivant Sciences and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Roivant Sciences' score of 0.52 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Roivant Sciences has higher earnings, but lower revenue than Ionis Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,270.55	-$299.77M	-$0.53	N/A
Ionis Pharmaceuticals	$944M	10.70	-$381.39M	-$3.46	N/A

Ionis Pharmaceuticals has a net margin of -64.76% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Roivant Sciences beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Moderna presently has a consensus target price of $56.56, suggesting a potential downside of 67.56%. Ionis Pharmaceuticals has a consensus target price of $94.15, suggesting a potential upside of 54.85%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.05
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Ionis Pharmaceuticals has a net margin of -64.76% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Ionis Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	35.81	-$2.82B	-$7.99	N/A
Ionis Pharmaceuticals	$944M	10.70	-$381.39M	-$3.46	N/A

75.3% of Moderna shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Moderna has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

In the previous week, Moderna had 40 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 50 mentions for Moderna and 10 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.65 beat Moderna's score of 0.67 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	28 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	6 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Ionis Pharmaceuticals beats Moderna on 10 of the 16 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IONS vs. The Competition

Export

Metric	Ionis Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.91B	$3.87B	$7.17B	$12.86B
Dividend Yield	N/A	3.66%	2.55%	10.29%
P/E Ratio	-17.57	11.71	268.96	24.23
Price / Sales	10.70	1,339.31	620.67	101.69
Price / Cash	N/A	102.56	78.23	52.73
Price / Book	22.94	17.25	13.25	6.25
Net Income	-$381.39M	-$12.52M	$3.47B	$348.04M
7 Day Performance	8.82%	4.41%	2.31%	-0.15%
1 Month Performance	14.83%	7.74%	5.39%	2.68%
1 Year Performance	42.02%	63.71%	29.20%	21.01%

Ionis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IONS Ionis Pharmaceuticals	3.4792 of 5 stars	$60.80 +2.0%	$94.15 +54.9%	+43.1%	$9.91B	$944M	N/A	1,402	Analyst Forecast
BIIB Biogen	3.8739 of 5 stars	$209.15 -0.3%	$227.07 +8.6%	+59.6%	$31.00B	$9.89B	37.02	7,500	Positive News
ALNY Alnylam Pharmaceuticals	4.7928 of 5 stars	$224.60 -1.8%	$393.86 +75.4%	-47.1%	$30.60B	$3.71B	41.75	2,770	Analyst Forecast Gap Up
INSM Insmed	3.3132 of 5 stars	$128.32 +3.7%	$205.52 +60.2%	+2.7%	$27.02B	$606.42M	N/A	1,664
ROIV Roivant Sciences	1.5341 of 5 stars	$36.24 +0.1%	$35.14 -3.0%	+218.0%	$26.15B	$8.26M	N/A	860	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IONS) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Ionis Pharmaceuticals compare to Biogen?

Summary

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Summary

How does Ionis Pharmaceuticals compare to Roivant Sciences?

Summary

How does Ionis Pharmaceuticals compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Ionis Pharmaceuticals compare to Biogen?

Which has stronger earnings and valuation, BIIB or IONS?

Do insiders & institutionals have more ownership in BIIB or IONS?

Is BIIB or IONS more profitable?

Which has more volatility & risk, BIIB or IONS?

Does the media prefer BIIB or IONS?

Do analysts prefer BIIB or IONS?

Summary

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Do insiders & institutionals hold more shares of ALNY or IONS?

Which has more volatility & risk, ALNY or IONS?

Does the media prefer ALNY or IONS?

Is ALNY or IONS more profitable?

Which has stronger valuation and earnings, ALNY or IONS?

Do analysts recommend ALNY or IONS?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Does the media refer more to IONS or INSM?

Which has stronger earnings and valuation, IONS or INSM?

Is IONS or INSM more profitable?

Do institutionals & insiders have more ownership in IONS or INSM?

Which has more risk and volatility, IONS or INSM?

Do analysts rate IONS or INSM?

Summary

How does Ionis Pharmaceuticals compare to Roivant Sciences?

Do analysts rate ROIV or IONS?

Which has more risk & volatility, ROIV or IONS?

Does the media favor ROIV or IONS?

Which has stronger earnings and valuation, ROIV or IONS?

Is ROIV or IONS more profitable?

Do institutionals and insiders have more ownership in ROIV or IONS?

Summary

How does Ionis Pharmaceuticals compare to Moderna?

Do analysts recommend MRNA or IONS?

Is MRNA or IONS more profitable?

Which has higher valuation and earnings, MRNA or IONS?

Do institutionals and insiders hold more shares of MRNA or IONS?

Which has more risk & volatility, MRNA or IONS?

Does the media favor MRNA or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools